Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Frontiers in Immunology|February 11, 2020
Polarization of Human Monocyte-Derived Cells With Vitamin D Promotes Control of Mycobacterium tuberculosis InfectionJagadeeswara Rao Muvva, Venkata Ramanarao Parasa, Maria Lerm, et al.
Journal of Visualized Experiments : Jove|October 5, 2020
Polarization of M1 and M2 Human Monocyte-Derived Cells and Analysis with Flow Cytometry upon Mycobacterium tuberculosis InfectionAkhirunnesa Mily, Sadaf Kalsum, Marco Giulio Loreti, et al.
The Journal of Infectious Diseases|February 19, 2021
Immunomodulatory Agents Combat Multidrug-Resistant Tuberculosis by Improving Antimicrobial ImmunityJagadeeswara Rao Muvva, Sultan Ahmed, Rokeya Sultana Rekha, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2018
Prostaglandin E2 suppresses hCAP18/LL-37 expression in human macrophages via EP2/EP4: implications for treatment of Mycobacterium tuberculosis infectionMin Wan, Xiao Tang, Rokeya Sultana Rekha, et al.
Autophagy|July 29, 2015
Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophagesRokeya Sultana Rekha, S S V Jagadeeswara Rao Muvva, Min Wan, et al.
The American Journal of Pathology|January 29, 2022
Immunosuppressive Features of the Microenvironment in Lymph Nodes Granulomas from Tuberculosis and HIV-Co-Infected PatientsSenait Ashenafi, Jagadeeswara Rao Muvva, Akhirunnesa Mily, et al.
European Journal of Immunology|April 28, 2016
In vivo engineering of mobilized stem cell grafts with the immunomodulatory drug FTY720 for allogeneic transplantationTadepally Lakshmikanth, Frank Heuts, S S V Jagadeeswara Rao Muvva, et al.
Genes and Immunity|November 2, 2024
The HLA-B -21 M/T dimorphism associates with disease severity in COVID-19Benedikt Strunz, Pouria Momayyezi, Eleni Bilev, et al.
Molecular Medicine (Cambridge, Mass.)|May 13, 2022
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccineCaroline Boulouis, Tobias Kammann, Angelica Cuapio, et al.
Plos One|December 29, 2023
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trialJonas Sundén-Cullberg, Puran Chen, Henrike Häbel, et al.
Pageof 2